Morphic Holding, Inc. – NASDAQ:MORF
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Morphic Holding stock price monthly change
+93.95%
month
Morphic Holding stock price quarterly change
+85.25%
quarter
Morphic Holding stock price yearly change
-8.02%
year
Morphic Holding key metrics
Market Cap | 2.86B |
Enterprise value | 1.29B |
P/E | -22.51 |
EV/Sales | 18.35 |
EV/EBITDA | -24.34 |
Price/Sales | 19.14 |
Price/Book | 3.88 |
PEG ratio | -0.53 |
EPS | -3.38 |
Revenue | N/A |
EBITDA | -192.52M |
Income | -161.25M |
Revenue Q/Q | -100% |
Revenue Y/Y | -100% |
Profit margin | -83.38% |
Oper. margin | -89.53% |
Gross margin | 0% |
EBIT margin | -89.53% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMorphic Holding stock price history
Morphic Holding stock forecast
Morphic Holding financial statements
| Jun 2023 | 60.23M | -39.01M | -64.77% |
|---|---|---|---|
| Sep 2023 | 0 | -36.21M | |
| Dec 2023 | -60.23M | -40.73M | 67.63% |
| Mar 2024 | 0 | -45.29M |
| 2025 | 750K | -228.78M | -30505.09% |
|---|---|---|---|
| 2026 | 857.14K | -250.07M | -29175.16% |
| 2027 | 1.5M | -210.85M | -14056.71% |
| 2028 | 153.45M | -145.06M | -94.53% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 748720000 | 19.35M | 2.59% |
|---|---|---|---|
| Sep 2023 | 743602000 | 20.43M | 2.75% |
| Dec 2023 | 722514000 | 25.49M | 3.53% |
| Mar 2024 | 682765000 | 19.18M | 2.81% |
| Jun 2023 | -23.03M | -133.21M | 331.62M |
|---|---|---|---|
| Sep 2023 | -29.25M | -133.08M | 19.28M |
| Dec 2023 | -28.57M | 12.88M | 34K |
| Mar 2024 | -46.38M | 31.36M | 911K |
Morphic Holding alternative data
| Aug 2023 | 107 |
|---|---|
| Sep 2023 | 110 |
| Oct 2023 | 110 |
| Nov 2023 | 110 |
| Dec 2023 | 115 |
| Jan 2024 | 115 |
| Feb 2024 | 115 |
| Mar 2024 | 121 |
| Apr 2024 | 121 |
| May 2024 | 124 |
| Jun 2024 | 124 |
| Jul 2024 | 124 |
Morphic Holding other data
38.04%
-42.42%
of MORF is owned by hedge funds
66
-43
14.49M
-16.47M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 0 | 20000 |
| Nov 2023 | 4776 | 0 |
| Jan 2024 | 0 | 35876 |
| Jul 2024 | 0 | 125790 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SCHEGERIN MARC officer: CFO and COO | Common Stock | 43,936 | $55.8 | $2,451,629 | ||
Option | SCHEGERIN MARC officer: CFO and COO | Employee Stock Option (right to buy) | 43,936 | $15 | $659,040 | ||
Option | TIPIRNENI PRAVEEN P. director, officer.. | Employee Stock Option (right to buy) | 21,582 | $4.32 | $93,126 | ||
Option | TIPIRNENI PRAVEEN P. director, officer.. | Common Stock | 21,582 | $4.32 | $93,126 | ||
Sale | TIPIRNENI PRAVEEN P. director, officer.. | Common Stock | 21,582 | $55.79 | $1,204,081 | ||
Option | ROGERS BRUCE officer: PRESIDENT | Common Stock | 20,000 | $4.32 | $86,300 | ||
Option | FARRELL ROBERT E JR officer: SVP Finance and CAO | Employee Stock Option (right to buy) | 8,786 | $4.32 | $37,912 | ||
Option | DEVAUL WILLIAM officer: General Counsel and Se.. | Employee Stock Option (right to buy) | 10,000 | $4.32 | $43,150 | ||
Option | DEVAUL WILLIAM officer: General Counsel and Se.. | Common Stock | 10,000 | $4.32 | $43,150 | ||
Sale | DEVAUL WILLIAM officer: General Counsel and Se.. | Common Stock | 10,000 | $55.79 | $557,910 |
| Quarter | Transcript |
|---|---|
| Q4 2020 1 Mar 2021 | Q4 2020 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Praveen P. Tipirneni M.D. (1968) Chief Executive Officer, Pres & Director | $936,320 |
Dr. Marc Schegerin M.B.A., M.D. (1976) Chief Financial Officer & Chief Operating Officer | $597,090 |
| Dr. Timothy A. Springer Ph.D. (1948) Founder, Independent Director & Member of Scientific Advisory Board | $35,000 |
Morphic: High Valuation Not Justified By Data, Development Status, Or Cash
Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023
Morphic Holding: Potentially The Next Prometheus Biosciences
Morphic Holding: Technical Case For Tactical Medium-Term Buy (Technical Analysis)
Morphic: Pioneering Integrin Medicines
-
When is Morphic Holding's next earnings date?
Unfortunately, Morphic Holding's (MORF) next earnings date is currently unknown.
-
Does Morphic Holding pay dividends?
No, Morphic Holding does not pay dividends.
-
How much money does Morphic Holding make?
Morphic Holding has a market capitalization of 2.86B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 99.26% to 521K US dollars.
-
What is Morphic Holding's stock symbol?
Morphic Holding, Inc. is traded on the NASDAQ under the ticker symbol "MORF".
-
What is Morphic Holding's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Morphic Holding?
Shares of Morphic Holding can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Morphic Holding's key executives?
Morphic Holding's management team includes the following people:
- Dr. Praveen P. Tipirneni M.D. Chief Executive Officer, Pres & Director(age: 57, pay: $936,320)
- Dr. Marc Schegerin M.B.A., M.D. Chief Financial Officer & Chief Operating Officer(age: 49, pay: $597,090)
- Dr. Timothy A. Springer Ph.D. Founder, Independent Director & Member of Scientific Advisory Board(age: 77, pay: $35,000)
-
Is Morphic Holding founder-led company?
Yes, Morphic Holding is a company led by its founder Dr. Timothy A. Springer Ph.D..
-
How many employees does Morphic Holding have?
As Jul 2024, Morphic Holding employs 124 workers, which is 2% more then previous quarter.
-
When Morphic Holding went public?
Morphic Holding, Inc. is publicly traded company for more then 6 years since IPO on 27 Jun 2019.
-
What is Morphic Holding's official website?
The official website for Morphic Holding is morphictx.com.
-
Where are Morphic Holding's headquarters?
Morphic Holding is headquartered at 35 Gatehouse Drive, A2, Waltham, MA.
-
How can i contact Morphic Holding?
Morphic Holding's mailing address is 35 Gatehouse Drive, A2, Waltham, MA and company can be reached via phone at +7 819960955.
Morphic Holding company profile:
Morphic Holding, Inc.
morphictx.comExchange:
NASDAQ
Full time employees:
128
Industry:
Biotechnology
Sector:
Healthcare
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
35 Gatehouse Drive, A2
Waltham, MA 02451
Waltham, MA 02451
CIK: 0001679363
ISIN: US61775R1059
CUSIP: 61775R105
